The effects of vasoactive drugs on the retinal circulation.
D008725:Bis-Trimethylammonium Compounds / Q000627:therapeutic use; D001965:Bromides / Q000627:therapeutic use; D004877:Ergoloid Mesylates / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006830:Hydralazine / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy*; D009388:Neostigmine / Q000627:therapeutic use; D009539:Nicotinic Acids / Q000627:therapeutic use; D005996:Nitroglycerin / Q000627:therapeutic use; D010208:Papaverine / Q000627:therapeutic use; D010634:Phenobarbital / Q000627:therapeutic use; D010646:Phentolamine / Q000627:therapeutic use; D008517:Phytotherapy; D010946:Plants, Medicinal; D010947:Plants, Toxic; D011343:Procaine / Q000627:therapeutic use; D011526:Protoveratrines / Q000627:therapeutic use; D012039:Regional Blood Flow / Q000187:drug effects*; D012110:Reserpine / Q000627:therapeutic use; D012171:Retinal Vessels / Q000187:drug effects*; D012607:Scotoma / Q000188:drug therapy; D014043:Tolazoline / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use*; D014703:Veratrum / Q000627:therapeutic use
D008725:Bis-Trimethylammonium Compounds; D001965:Bromides; D009539:Nicotinic Acids; D011526:Protoveratrines; D014665:Vasodilator Agents; D006830:Hydralazine; D009388:Neostigmine; D011343:Procaine; D004877:Ergoloid Mesylates; D012110:Reserpine; D006493:Heparin; D014043:Tolazoline; D010208:Papaverine; D005996:Nitroglycerin; D010634:Phenobarbital; D010646:Phentolamine